Jessica Friedeman Sells 30,000 Shares of LifeMD, Inc. (NASDAQ:LFMD) Stock

LifeMD, Inc. (NASDAQ:LFMD) CMO Jessica Friedeman sold 30,000 shares of the stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $5.66, for a total value of $169,800.00. Following the sale, the chief marketing officer now directly owns 170,000 shares of the company’s stock, valued at approximately $962,200. This trade represents a 15.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

LifeMD Stock Down 3.9 %

NASDAQ:LFMD traded down $0.23 during trading hours on Monday, hitting $5.71. 1,491,039 shares of the stock traded hands, compared to its average volume of 798,587. The company has a market cap of $254.57 million, a price-to-earnings ratio of -8.92 and a beta of 1.50. LifeMD, Inc. has a 1 year low of $3.99 and a 1 year high of $12.88. The stock has a 50 day moving average price of $5.68 and a 200 day moving average price of $5.39.

LifeMD (NASDAQ:LFMD) last released its earnings results on Monday, March 10th. The company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.02. The firm had revenue of $64.26 million for the quarter, compared to analysts’ expectations of $57.43 million. Equities analysts forecast that LifeMD, Inc. will post -0.56 earnings per share for the current fiscal year.

Institutional Trading of LifeMD

Several institutional investors have recently made changes to their positions in the business. Prudential Financial Inc. grew its holdings in LifeMD by 19.3% during the 4th quarter. Prudential Financial Inc. now owns 13,605 shares of the company’s stock valued at $67,000 after buying an additional 2,200 shares in the last quarter. Rhumbline Advisers increased its holdings in LifeMD by 6.1% in the 4th quarter. Rhumbline Advisers now owns 48,689 shares of the company’s stock valued at $241,000 after acquiring an additional 2,814 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in LifeMD by 26.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,012 shares of the company’s stock worth $70,000 after purchasing an additional 2,895 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of LifeMD by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 822,217 shares of the company’s stock valued at $4,071,000 after purchasing an additional 2,984 shares during the last quarter. Finally, Magnus Financial Group LLC lifted its position in shares of LifeMD by 31.1% in the fourth quarter. Magnus Financial Group LLC now owns 16,000 shares of the company’s stock worth $79,000 after buying an additional 3,792 shares in the last quarter. Hedge funds and other institutional investors own 35.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on LFMD shares. Cantor Fitzgerald reissued an “overweight” rating and set a $15.00 price objective on shares of LifeMD in a research note on Tuesday, March 11th. B. Riley upgraded LifeMD to a “strong-buy” rating in a research note on Tuesday, March 11th. Mizuho initiated coverage on LifeMD in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $7.00 price target for the company. KeyCorp lowered their target price on shares of LifeMD from $10.00 to $7.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Finally, HC Wainwright boosted their price objective on shares of LifeMD from $12.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday, March 12th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, LifeMD presently has a consensus rating of “Buy” and an average price target of $11.43.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.